Modeling methamphetamine use disorder and relapse in animals: short- and long-term epigenetic, transcriptional., and biochemical consequences in the rat brain

Methamphetamine use disorder (MUD) is a complex, chronic neuropsychiatric condition characterized by binge drug intake, cycles of abstinence, and a high rate of relapse. While behavioral models in rodents have successfully replicated these patterns, researchers continue to work toward identifying the underlying molecular drivers. This paper reviews existing data on differentially expressed genes (DEGs) in the rat dorsal striatum following methamphetamine self-administration to pinpoint potential targets for new pharmacological interventions.

The researchers analyzed striatal gene expression at three distinct time points: 2 hours, 24 hours, and 1 month after the final methamphetamine session. Their findings highlight several key systems that undergo significant modification:

• Potassium Channels: Increased expression of several potassium channel genes (e.g., Kcnh2, Kcns3) suggests a critical role in regulating neuronal excitability and dopamine release. Activating these channels may hold promise for suppressing compulsive drug-taking.
• Neuroimmune Signaling: At 24 hours post-abstinence, the study observed widespread changes in genes linked to neuroinflammation, suggesting that methamphetamine significantly disrupts the brain’s immune environment, which may influence long-term clinical manifestations.
• Synaptic Plasticity: Long-term abstinence (1 month) is marked by a shift in genes related to the actin cytoskeleton (e.g., Anln, Mypn). These changes likely reflect persistent remodeling of synaptic architecture, a process fundamentally linked to the memory of drug-related cues and the incubation of drug craving.

Current treatments for MUD often struggle to address the biological heterogeneity of the disorder. By cataloging the gene expression networks activated by methamphetamine, the authors provide a foundational map for developing more targeted, mechanism-based therapies. The study emphasizes that because drug-induced neuroadaptations are time-dependent, therapeutic strategies should be tailored to the patient’s stage of abstinence—whether they are in the acute withdrawal phase or managing long-term recovery.